The Only Monthly Membership With a Positive ROI!

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Contribute

España

India

Italia

대한민국

日本

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Research

My Stocks

Tools

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Trade Ideas

Unusual Options Activity

Short Interest

Calculators

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

NRX Pharmaceuticals

NRXPWNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.068100

00.00%

At close: Jul 24, 1:43 PM EDT

$0.100000

0.0346.84%

After Hours: Jul 8, 6:01 PM EDT

15 minutes delayed

NRX Pharmaceuticals (NRXPW) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for NRX Pharmaceuticals (NASDAQ:NRXPW) Stock

NRX Pharmaceuticals Stock (NASDAQ: NRXPW)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, April 01, 2024

Trading Halt: Halted at 7:50:00 p.m. ET - Tra...
Benzinga Newsdesk

Thursday, October 14, 2021

EXCLUSIVE: NRx Pharmaceuticals CEO Jonathan Javitt, On Co.'s Trial Data Of Aviptadil, Says 'The improvement in the test group's overall respiratory distress ratio and cytokine levels add biologic credibility to the positive findings from this study'
Zoltan Suranyi

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

NRX Pharmaceuticals

News

Latest news for NRX Pharmaceuticals (NASDAQ:NRXPW) Stock

Monday, April 01, 2024

Thursday, October 14, 2021

People Also Watch